NCT03648489 2024-09-20
DICE
Imperial College London
Phase 2 Completed
Clinical Trials
17 trialsNCT04479306 2024-06-04
Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03097328 2024-04-29
Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02244463 2024-01-12
A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT03017833 2023-10-04
Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03193853 2023-08-07
TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer
Baylor Research Institute
Phase 2 Completed
NCT02575339 2022-07-26
MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
Big Ten Cancer Research Consortium
Phase 1/2 Terminated
NCT03430882 2022-06-21
Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Completed
NCT05022394 2022-05-27
Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT02988986 2021-09-22
ANETT
The Methodist Hospital Research Institute
Phase 2 Completed
NCT02514824 2020-12-29
MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT02619669 2020-03-12
Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer
Dartmouth-Hitchcock Medical Center
Phase 1 Withdrawn
NCT02727777 2020-03-12
Phase II Study of TAK228 in Relapsed Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT02091531 2019-11-21
Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03745911 2018-11-19
Paclitaxel and TAK-228 in Urothelial Carcinoma
Associació per a la Recerca Oncologica, Spain
Phase 2 Unknown
NCT03205891 2018-01-17
Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT02812056 2017-03-27
Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies
M.D. Anderson Cancer Center
Phase 1 Withdrawn